Format

Send to

Choose Destination
J Enzyme Inhib Med Chem. 2019 Dec;34(1):375-387. doi: 10.1080/14756366.2018.1497619.

Synthesis and biological evaluation of novel N9-heterobivalent β-carbolines as angiogenesis inhibitors.

Author information

1
a School of Chemistry and Chemical Engineering/Key Laboratory for Green Processing of Chemical Engineering of XinJiang Bingtuan , Shihezi University , Shihezi , China.
2
b XinJiang Huashidan Pharmaceutical Research Co. Ltd. , Urumqi , China.

Abstract

A series of novel N9-heterobivalent β-carbolines has been synthesized. All the novel compounds were tested for their anticancer activity against six tumour cell lines in vitro. Among these molecules, compounds 5b, and 5w exhibited strong cytotoxic activities with IC50 value of lower than 20 μM. Acute toxicities and antitumor efficacies of the selected compounds in mice were also evaluated, compounds 5b and 5w exhibited that tumour inhibition rate of over 40% in the Sarcoma 180 and Lewis lung cancer animal models. Preliminary structure-activity relationships (SARs) analysis indicated that: (1) C1-methylation and C7-methoxylation were favorable for increased activities; (2) 3-Pyridyl or 2-thienyl group substituent into position-1 of the β-carboline core, and the aryl substituent into another β-carboline ring might be detrimental to cytotoxic effects of this class compounds. Investigation of the preliminary mechanism of action demonstrated that compound 5b had obvious angiogenesis inhibitory effects in the chicken chorioallantoic membrane (CAM) assay.

KEYWORDS:

Heterobivalent β-carboline; angiogenesis inhibitors; cytotoxic activities; structure–activity relationship

PMID:
30734606
PMCID:
PMC6327987
DOI:
10.1080/14756366.2018.1497619
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center